Acumen Pharma (Pvt) Ltd has entered into a strategic Memorandum of Understanding (MoU) with the Feminine Healthcare Scientific Committee (FHC360 World Congress) to strengthen collaboration in medical education, scientific exchange, and innovation in women’s healthcare.
The agreement was signed on 15 July 2024 between Acumen Pharma and FHC360, a globally recognized platform focused on advancing healthcare education and scientific collaboration.
Under this partnership, both organizations will work together on:
- Continuing Medical Education (CME) activities
- National and international scientific conferences
- Workshops and academic forums
- Women’s healthcare awareness and educational programs
- Research-oriented and interdisciplinary scientific events
The collaboration also includes support for expert lectures, panel discussions, training workshops, and the exchange of scientific expertise and educational resources.
As part of the agreement, Acumen Pharma will contribute through educational sponsorships, logistical support, promotional outreach, and industry collaboration, while FHC360 will lead scientific planning, faculty coordination, and academic quality assurance for events and initiatives.
This MoU reflects the shared commitment of both organizations toward improving professional medical education, promoting scientific innovation, and enhancing women’s healthcare through collaborative initiatives on both national and international levels.
The MoU details can be found here